Clinical trials: Androgens
Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
This phase II trial studies the effect of erdafitinib in treating patients with prostate cancer that grows and continues to spread despite the surgical removal of the testes or drugs to block androgen production…
- Conditions
- Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Adenocarcinoma
- Trial name
- NCT04754425
- Testing
- Biopsy, Biospecimen Collection, Erdafitinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Response
Human Chorionic Gonadotropin (hCG) Priming Prior to Controlled Ovarian Hyperstimulation (COH) in Poor Responder In Vitro Fertilization (IVF) Patients
There is a decline in androgen concentration with ovarian aging. Also, ovarian response to COH in IVF cycles diminishes with ovarian aging.
- Trial name
- APPE (NCT00870025)
- Testing
- human chorionic gonadotropin
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- IVI Madrid
Prostatic Neoplasms
Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer
To evaluate the efficacy and safety of Trovax and GM-CSF in patients with prostate cancer.
- Trial name
- NCT00448409
- Testing
- TroVax, GM-CSF
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- The Methodist Hospital Research Institute
Polycystic Ovary Syndrome (PCOS)
Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women
The purpose of this research study is to collect specimen samples and study medical information from women with Polycystic Ovary Syndrome (PCOS) and women without PCOS.
- Trial name
- NCT01889199
- Testing
- Flutamide
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Prostate Adenocarcinoma, Prostate Cancer
Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
The goal of this research study is to determine whether hormonal therapies used early in the course of prostate cancer could increase the amount of Prostate-Specific Membrane Antigen (PSMA) as detected by PET/CT scans for…
- Conditions
- Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Trial name
- NCT05683964
- Testing
- Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi], Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Beth Israel Deaconess Medical Center
Prostatic Neoplasm
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
The purpose of this study is to evaluate the efficacy and safety of AAA617 alone (Lutetium [177Lu] vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in participants with PSMA-positive…
- Trial name
- PSMACare (NCT05849298)
- Testing
- AAA617, AAA517, Piflufolastat F 18
- Where
- 31 sites in United States, Brazil and 9 more
- Volunteers
- 49 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Men, Male Contraception
Single Dose, Dose-Ranging Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men
The long term objective is to develop a new male hormone 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) as a male hormonal contraceptive.
- Trial name
- CCN014 (NCT02754687)
- Testing
- 11βmethyl nortestosterone dodecylcarbonate
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Premier Research
Prostate Cancer
Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2
This study will explore the combination of a stereotactic body radiation therapy (SBRT) approach combined with one year of luteinizing hormone releasing hormone (LHRH) agonist for older men with high risk prostate cancer, or men…
- Trial name
- FASTR-2 (NCT02229734)
- Testing
- Radiation, Androgen Suppression
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Prostate Cancer, Adenocarcinoma of the Prostate
Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone
The main purpose of this study is to look at the effects (good or bad) that Atrasentan given alone and Atrasentan given with Zometa has on levels of bone formation and bone destruction in men with prostate cancer that has spread…
- Trial name
- NCT00181558
- Testing
- Atrasentan, Zoledronic Acid (Zometa)
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Massachusetts General Hospital
Prostate Cancer
Radiation Therapy and Hormone Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high energy x-rays to damage tumor cells. Hormone therapy combined with radiation therapy may be a more effective treatment for prostate cancer.
- Trial name
- NCT00769548
- Testing
- flutamide, goserelin acetate, low-LET photon therapy
- Volunteers
- 1,322 people
- Sponsor
- Radiation Therapy Oncology Group
Hirsutism
Bone Status and Insulin Resistance in Hirsutism
The purpose of this study is to investigate how the bones of hirsute women are different from bones of healthy women. The change in hormone content in the blood will also be investigated.
- Trial name
- NCT00143052
- Where
- Denmark
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Prostate Cancer
Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer
This Phase II study is designed to study the clinical and radiologic response, as well as, safety and tolerability of abemaciclib in combination with androgen deprivation therapy (ADT) in patients with localized high-risk or…
- Trial name
- RAD 1805 (NCT04298983)
- Testing
- Abemaciclib 150 MG by mouth twice daily, Androgen deprivation therapy (ADT), Radiation Therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Alabama at Birmingham
Prostate Cancer
Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging
This is a pilot, non-randomized, two-cohort interventional study in patients who meet the inclusion criteria, using an FDA- approved androgen deprivation agent for a 3 or 6-week course of treatment prior to standard-of-care RALP…
- Trial name
- PIONEER PSMA (NCT07069465)
- Testing
- flotufolastat F 18, Relugolix 120 MG, Serum PSA and Testosterone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Urology Clinics of North Texas
Prostate Cancer
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
This was a Phase 3b clinical study in prostate cancer patients which aimed to compare the current standard therapy of a gonadotrophin releasing hormone (GnRH) agonist, goserelin (3.6 mg; plus anti-androgen flare protection…
- Trial name
- NCT00884273
- Testing
- Degarelix, Goserelin, Bicalutamide
- Where
- 46 sites in Belgium, Denmark and 6 more
- Volunteers
- 182 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
PROState Cancer Patients Initiating Hormone Therapy: Effect of Exercise on CARDIOvascular Health (PROSCARDIO)
This study evaluates whether exercise can reduce treatment-related adverse effects in prostate cancer patients initiating androgen deprivation therapy.
- Trial name
- PROSCARDIO (NCT03776045)
- Testing
- Standard care plus exercise
- Volunteers
- 50 people
- Sponsor
- University of East Anglia
Acne Vulgaris
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve hours for two weeks, in pediatric patients 9…
- Trial name
- NCT02720627
- Testing
- cortexolone 17α-propionate
- Where
- 10 sites in United States, Poland
- Volunteers
- 27 people
- Sponsor
- Cassiopea SpA
Prostate Cancer
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients
This is a single institution, open label, phase II study in androgen-independent prostate cancer patients who are chemotherapy-naïve.
- Trial name
- NCT00654186
- Testing
- Revlimid
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Oncology Specialists, S.C.
Prostate Cancer
Prostate MRI and Pylarify PSMA PET/CT
This is a voluntary research study to find out how using technology including advanced magnetic resonance imaging (MRI) and prostate-specific membrane antigen - positron emission tomography (PSMA-PET) scan imaging, in addition to…
- Trial name
- NCT05568537
- Testing
- Pylarify Piflufolastat Flourine-18 (18F-DCFPyL)
- Sponsor
- Corewell Health East
Infant Developmental Assessment
The Relationship Between Finger Ratio and Development in Infants
One of the most prominent indicators of prenatal androgen exposure is considered to be the ratio of second and fourth finger lengths (2D:4D).
- Trial name
- NCT07525726
- Testing
- Digit Ratio, Motor development, Sensory processing functions
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Nigde Omer Halisdemir University
Spinal and Bulbar Muscular Atrophy, Kennedys Disease
Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)
Background: SBMA is an inherited chronic disease. It affects males in mid to late adulthood. It causes slowly progressive weakness of muscles and hand tremors. Researchers want to learn more about the effects of SBMA.
- Conditions
- Spinal and Bulbar Muscular Atrophy, Kennedys Disease, Motor Neuron Disease
- Trial name
- NCT04944940
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.